These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23923400)

  • 1. Compounded preparations with nystatin for oral and oromucosal administration.
    Sklenár Z; Scigel V; Horácková K; Slanar O
    Acta Pol Pharm; 2013; 70(4):759-62. PubMed ID: 23923400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-layered mucoadhesive tablets containing nystatin.
    Llabot JM; Manzo RH; Allemandi DA
    AAPS PharmSciTech; 2002; 3(3):E22. PubMed ID: 12916937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted antifungal delivery system: beta-glucosidase sensitive nystatin-star poly(ethylene glycol) conjugate.
    Bílková E; Imramovský A; Buchta V; Sedlák M
    Int J Pharm; 2010 Feb; 386(1-2):1-5. PubMed ID: 19874880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of an Intralipid formulation of nystatin in murine systemic candidiasis.
    Semis R; Mendlovic S; Polacheck I; Segal E
    Int J Antimicrob Agents; 2011 Oct; 38(4):336-40. PubMed ID: 21839619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of dissolution of nystatin from buccoadhesive tablets containing various surfactants and a solid dispersion formulation.
    Sakeer K; Al-Zein H; Hassan I; Desai S; Nokhodchi A
    Arch Pharm Res; 2010 Nov; 33(11):1771-9. PubMed ID: 21116780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The possibilities of innovation of extemporaneous preparation in pharmacies in the Czech Republic].
    Sklenář Z; Horáčková K
    Ceska Slov Farm; 2012 Feb; 61(1-2):11-6. PubMed ID: 22536647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of extemporaneous pediatric oral liquids compounded from tablets and drug substance: case of propranolol and theophylline.
    Muśko M; Sznitowska M
    Acta Pol Pharm; 2013; 70(1):137-45. PubMed ID: 23610969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of chronic esophageal moniliasis with a viscous suspension of nystatin.
    Kantrowitz PA; Fleischli DJ; Butler WT
    Gastroenterology; 1969 Oct; 57(4):424-30. PubMed ID: 5212385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: ultrastructural effects and release studies.
    Fernández Campos F; Calpena Campmany AC; Rodríguez Delgado G; López Serrano O; Clares Naveros B
    J Pharm Sci; 2012 Oct; 101(10):3739-52. PubMed ID: 22777575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of novel antifungal mucoadhesive films Part I. Pre-formulation studies.
    Llabot JM; Palma SD; Manzo RH; Allemandi DA
    Int J Pharm; 2007 Feb; 330(1-2):54-60. PubMed ID: 17071026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nystatin and lidocaine pastilles for the local treatment of oral mucositis.
    Silva FC; Marto JM; Salgado A; Machado P; Silva AN; Almeida AJ
    Pharm Dev Technol; 2017 Mar; 22(2):266-274. PubMed ID: 27499389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of xanthan and its binary blends with synthetic polymers to design controlled release formulations of buccoadhesive nystatin tablets.
    Sakeer K; Al-Zein H; Hassan I; Martin GP; Nokhodchi A
    Pharm Dev Technol; 2010; 15(4):360-8. PubMed ID: 19772376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative formulation of nystatin particulate systems in toothpaste for candidiasis treatment.
    Pinto Reis C; Vasques Roque L; Baptista M; Rijo P
    Pharm Dev Technol; 2016; 21(3):282-7. PubMed ID: 25567611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin.
    El-Ridy MS; Abdelbary A; Essam T; El-Salam RM; Kassem AA
    Drug Dev Ind Pharm; 2011 Dec; 37(12):1491-508. PubMed ID: 21707323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit.
    Ozturk MA; Gunes T; Koklu E; Cetin N; Koc N
    Mycoses; 2006 Nov; 49(6):484-92. PubMed ID: 17022766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ex-vivo oral mucosa infection model for the evaluation of the topical activity of antifungal agents.
    Ohnemus U; Willers C; Bubenheim M; Horstkotte MA; Houdek P; Fischer F; Schmage P; Moll I; Brandner JM
    Mycoses; 2008 Jan; 51(1):21-9. PubMed ID: 18076591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral sustained release nystatin tablets for the treatment of oral candidiasis: formulation development and validation of UV spectrophotometric analytical methodology for content determination.
    de Aguiar MM; de Albuquerque RP; Marinho DS; Braga BR; Dornelas CB; Oliveira A; de Sousa VP; Torres SR; Alviano DS; Alviano CS; Cabral LM; Holandino C
    Drug Dev Ind Pharm; 2010 May; 36(5):594-600. PubMed ID: 19954405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active pharmaceutical ingredients available as substances for extemporaneous preparation in veterinary medicine in the Czech Republic.
    Sklenář Z; Horáčková K; Bakhouche H
    Ceska Slov Farm; 2014 Apr; 63(2):71-4. PubMed ID: 24870551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate.
    Groeschke J; Solassol I; Bressolle F; Pinguet F
    J Pharm Biomed Anal; 2006 Sep; 42(3):362-6. PubMed ID: 16740372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.